Panbela announces adoption of commission implementing decision from the ema for the orphan designation of ivospemin (sbp-101) in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

Minneapolis, jan. 19, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the european medicines agency (ema) committee for orphan medicinal products has issued the adoption of commission implementing decision relating to the designation of ivospemin (sbp-101) as an orphan medicinal product in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (pda). the commission adopted the decision on january 13, 2023 and it will be published for information in all official languages of the eu in the community register of orphan medicinal products (http://ec.europa.eu/health/documents/community-register/html/orphreg.htm). previously, the u.s. food and drug administration (fda) granted orphan drug designation to sbp-101.
PBLA Ratings Summary
PBLA Quant Ranking